Successful treatment of secukinumab in a ten-year old with generalized pustular psoriasis recalcitrant with conventional therapy
DOI:
https://doi.org/10.66344/jpad.v33i4.2321Keywords:
generalized pustular psoriasis, secukinumab, biologic agent, pediatricAbstract
Currently there is a lack of standardized treatment guidelines for pediatric psoriasis treatment using biologic agents. Children are among special population usually excluded from clinical trials, therefore making guidelines more challenging to be published. Especially in generalized pustular psoriasis, a rare form of psoriasis, recalcitrant and difficult to manage cases of pediatric psoriasis may require more options than topical, phototherapy or systemic treatments. We present a case of a ten-year-old female diagnosed with generalized pustular psoriasis in the last four years, successfully treated with secukinumab after years of treatment to no avail
References
1. Ho PH, Tsai TF. Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: A case report and review of published work. J Dermatol. 2018;45:1353–6.
2. Posso-De Los Rios CJ, Pope E, Lara-Corrales I. A systematic review of systemic medications for pustular psoriasis in pediatrics. Pediatr Dermatol. 2014;31:430–9.
3. Nagai M, Imai Y, Wada Y, Kusakabe M, Yamanishi K. Serum procalcitonin and presepsin levels in patients with generalized pustular psoriasis. Dis Markers. 2018;2018.
4. Bodemer C, Kaszuba A, Kingo K, Tsianakas A, Morita A, Rivas E, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial. J Eur Acad Dermatology Venereol. 2021;35:938–47.
5. Cline A, Bartos GJ, Strowd LC, Feldman SR. Biologic Treatment Options for Pediatric Psoriasis and Atopic Dermatitis. Children. 2019;6:103.
6. British Association of Dermatologists. British Association of Dermatologists Guidelines for biologic therapy for psoriasis Methods, evidence and recommendations. 2017;1–390.
7. Wells LE, Evans T, Hilton R, Wine Lee L, Ruth N. Use of secukinumab in a pediatric patient leads to significant improvement in nail psoriasis and psoriatic arthritis. Pediatr Dermatol. 2019;36:384–5.
8. Sun HY, Phan K, Paller AS, Sebaratnam DF. Biologics for pediatric psoriasis: A systematic review and meta-analysis. Pediatr Dermatol. 2022;39:42–8.
9. Nast A, Spuls PI, van der Kraaij G, Gisondi P, Paul C, Ormerod AD, et al. European S3-Guideline on the systemic treatment of psoriasis vulgaris – Update Apremilast and Secukinumab – EDF in cooperation with EADV and IPC. J Eur Acad Dermatology Venereol. 2017;31:1951–63.
10. Xie X, Wang Y, Yao S, Xia Y, Luo H, Li L, et al. Biologics recommendations for patients with psoriasis: a critical appraisal of clinical practice guidelines for psoriasis. J Dermatolog Treat. 2022;33:2038–50.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Windy Keumala Budianti, Arlha Aporia Debinta, Riesye Arisanti, Andira Hardjodipuro
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
